Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Strong Earnings

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s stock price gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $19.81, but opened at $22.48. Amphastar Pharmaceuticals shares last traded at $21.92, with a volume of 146,469 shares trading hands.

The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The business had revenue of $183.90 million during the quarter, compared to analyst estimates of $179.92 million.

Trending Headlines about Amphastar Pharmaceuticals

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Adjusted EPS beat estimates: Amphastar reported adjusted earnings of $0.91 per share, up from $0.85 a year earlier and above consensus estimates ranging from $0.62 to $0.66. GAAP earnings were $0.67 per share. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue also topped expectations: Second-quarter net revenue was $183.9 million, compared with analysts’ average estimate of approximately $179.9 million. The company generated $30.3 million in GAAP net income and $40.8 million in adjusted net income. Amphastar Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Profitability remains solid: Amphastar reported an 11.0% net margin and 15.12% return on equity, while its quick and current ratios of 2.82 and 3.85 indicate substantial short-term liquidity. These figures support the stock’s favorable reaction to the earnings release. Amphastar Quarterly Earnings Results
• Neutral Sentiment: Investors will likely focus next on management’s outlook and commentary from the Q2 earnings call, particularly whether the earnings momentum can continue. Amphastar Q2 2026 Earnings Call Transcript

Analysts Set New Price Targets

AMPH has been the subject of a number of research reports. Barclays reduced their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, June 3rd. Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Wells Fargo & Company lifted their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday. Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Jefferies Financial Group restated a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Six analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $22.17.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Rice Hall James & Associates LLC lifted its holdings in Amphastar Pharmaceuticals by 54.6% in the first quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company’s stock valued at $3,670,000 after buying an additional 66,172 shares during the period. Denali Advisors LLC grew its holdings in Amphastar Pharmaceuticals by 56.9% during the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock worth $5,671,000 after acquiring an additional 76,765 shares during the period. Pacer Advisors Inc. raised its position in shares of Amphastar Pharmaceuticals by 47.1% during the 1st quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock valued at $5,122,000 after acquiring an additional 83,739 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock valued at $39,726,000 after acquiring an additional 228,262 shares during the last quarter. Finally, Cibc World Market Inc. bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth $1,666,000. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 9.7%

The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The business has a 50 day moving average of $19.63 and a 200 day moving average of $21.40. The firm has a market capitalization of $957.86 million, a price-to-earnings ratio of 13.09, a PEG ratio of 4.27 and a beta of 0.89.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.